Back

WuXi XDC signs second ADC partnership with Ona Therapeutics

Verifying
  • WuXi XDC granted Ona Therapeutics an exclusive global license for WuXiTecan-2 technology.
  • The agreement covers one ADC target, upfront and milestone payments, and tiered royalties.
  • The companies’ second ADC partnership follows their 2024 collaboration on Ona’s pipeline.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.